Publications by authors named "Steven Snapinn"

Claim this Profile
I
Improving Collection and Analysis of Overall Survival Data.
Lisa R Rodriguez, Nicole J Gormley, Ruixiao Lu, Anup K Amatya, George D Demetri, Steven Snapinn

Clin Cancer Res· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Analysis of on-treatment cancer safety events with daprodustat versus conventional erythropoiesis-stimulating agents-post hoc analyses of the ASCEND-ND and ASCEND-D trials.
Ajay K Singh, Finnian R McCausland, Brian L Claggett, Christoph Wanner, Andrzej Wiecek, Steven Snapinn

Nephrol Dial Transplant· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment effect measures under nonproportional hazards.
Steven Snapinn, Qi Jiang, Chunlei Ke

Pharm Stat· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Daprodustat and On-Treatment Cardiovascular Events in Chronic Kidney Disease. Reply.
Finnian R Mc Causland, Ajay K Singh, Brian L Claggett, Kevin Carroll, Janet Wittes, Steven Snapinn

N Engl J Med· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A shrinkage estimator for subgroup analysis without the exchangeability assumption.
Steven Snapinn

J Biopharm Stat· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Content Validity of HIT-6 as a Measure of Headache Impact in People With Migraine: A Narrative Review.
Carrie R Houts, R J Wirth, James S McGinley, Chad Gwaltney, Eric Kassel, Steven Snapinn

Headache· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
University of Pennsylvania 10th annual conference on statistical issues in clinical trials: Current issues regarding data and safety monitoring committees in clinical trials (morning panel session).
Barry Davis, David Kerr, Maureen Maguire, Corsee Sanders, Steven Snapinn

Clin Trials· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Some remaining challenges regarding multiple endpoints in clinical trials.
Steven Snapinn

Stat Med· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Responsibilities of Data Monitoring Committees: Consensus Recommendations.
Barbara E Bierer, Rebecca Li, Jonathan Seltzer, Lynn A Sleeper, Elizabeth Frank, Steven Snapinn

Ther Innov Regul Sci· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Statistical Considerations on the Evaluation of Imbalances of Adverse Events in Randomized Clinical Trials.
Haijun Ma, Chunlei Ke, Qi Jiang, Steven Snapinn

Ther Innov Regul Sci· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Choosing Appropriate Metrics to Evaluate Adverse Events in Safety Evaluation.
Ying Zhou, Chunlei Ke, Qi Jiang, Seta Shahin, Steven Snapinn

Ther Innov Regul Sci· May 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pure and hybrid causal effects on variables associated with an incident event.
Qi Jiang, Steven Snapinn

J Biopharm Stat· February 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Remaining Challenges in Assessing Non-Inferiority.
Steven Snapinn, Qi Jiang

Ther Innov Regul Sci· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The issue of multiplicity in noninferiority studies.
Chunlei Ke, Beiying Ding, Qi Jiang, Steven M Snapinn

Clin Trials· December 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Indirect comparisons in the comparative efficacy and non-inferiority settings.
Steven Snapinn, Qi Jiang

Pharm Stat· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predicting analysis time in event-driven clinical trials with event-reporting lag.
Jianming Wang, Chunlei Ke, Qi Jiang, Charlie Zhang, Steven Snapinn

Stat Med· April 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
On the clinical meaningfulness of a treatment's effect on a time-to-event variable.
Steven Snapinn, Qi Jiang

Stat Med· August 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Statins for secondary prevention of cardiovascular disease: the right dose.
Reynold Spector, Steven M Snapinn

Pharmacology· June 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Analysis of multiple endpoints in clinical trials: it's time for the designations of primary, secondary and tertiary to go.
Steven Snapinn, Qi Jiang

Pharm Stat· May 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Commentary.
Steven Snapinn

Pharm Stat· May 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predictors of cardiovascular events in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention for Endpoint reduction in hypertension study.
Sverre E Kjeldsen, Richard B Devereux, Darcy A Hille, Paulette A Lyle, Björn Dahlöf, Steven M Snapinn

Blood Press· February 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Moderate alcohol consumption is associated with reduced long-term cardiovascular risk in patients following a complicated acute myocardial infarction.
Trygve Brügger-Andersen, Volker Pönitz, Steven Snapinn, Kenneth Dickstein,

Int J Cardiol· April 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preservation of effect and the regulatory approval of new treatments on the basis of non-inferiority trials.
Steven Snapinn, Qi Jiang

Stat Med· February 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Controlling the type 1 error rate in non-inferiority trials.
Steven Snapinn, Qi Jiang

Stat Med· February 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Responder analyses and the assessment of a clinically relevant treatment effect.
Steven M Snapinn, Qi Jiang

Trials· October 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis